Denali Accounts Payable from 2010 to 2024
| DNLI Stock | USD 24.50 0.19 0.77% |
Accounts Payable | First Reported 2015-12-31 | Previous Quarter 13.9 M | Current Value 9.6 M | Quarterly Volatility 3.4 M |
Check Denali Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Denali Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 17.6 M, Interest Expense of 8.6 M or Selling General Administrative of 54.3 M, as well as many indicators such as Price To Sales Ratio of 8.47, Dividend Yield of 0.0 or PTB Ratio of 2.17. Denali financial statements analysis is a perfect complement when working with Denali Therapeutics Valuation or Volatility modules.
Denali | Accounts Payable |
Latest Denali Therapeutics' Accounts Payable Growth Pattern
Below is the plot of the Accounts Payable of Denali Therapeutics over the last few years. An accounting item on the balance sheet that represents Denali Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Denali Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Denali Therapeutics' Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Denali Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Accounts Payable | 10 Years Trend |
|
Accounts Payable |
| Timeline |
Denali Accounts Payable Regression Statistics
| Arithmetic Mean | 3,167,877 | |
| Geometric Mean | 2,492,374 | |
| Coefficient Of Variation | 88.25 | |
| Mean Deviation | 1,962,069 | |
| Median | 1,891,000 | |
| Standard Deviation | 2,795,796 | |
| Sample Variance | 7.8T | |
| Range | 8.9M | |
| R-Value | 0.70 | |
| Mean Square Error | 4.3T | |
| R-Squared | 0.48 | |
| Significance | 0 | |
| Slope | 434,764 | |
| Total Sum of Squares | 109.4T |
Denali Accounts Payable History
About Denali Therapeutics Financial Statements
Investors use fundamental indicators, such as Denali Therapeutics' Accounts Payable, to determine how well the company is positioned to perform in the future. Although Denali Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Accounts Payable | 9.5 M | 10 M |
Currently Active Assets on Macroaxis
When determining whether Denali Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Denali Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Denali Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Denali Therapeutics Stock:Check out the analysis of Denali Therapeutics Correlation against competitors. For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Denali Therapeutics. If investors know Denali will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Denali Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.76) | Quarterly Revenue Growth (1.00) | Return On Assets (0.24) | Return On Equity (0.35) |
The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Denali Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Denali Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Denali Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.